This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACHL Achilles Therapeutics (ACHL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock About Achilles Therapeutics Stock (NASDAQ:ACHL) Get Achilles Therapeutics alerts:Sign Up Key Stats Today's Range$1.48▼$1.4850-Day Range$1.48▼$1.4852-Week Range$0.63▼$1.51VolumeN/AAverage Volume744,051 shsMarket Capitalization$60.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom. Read More Receive ACHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACHL Stock News HeadlinesAchilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC DeregistrationFebruary 28, 2025 | markets.businessinsider.comAchilles Therapeutics announces voluntary Nasdaq delisting, SEC deregistrationFebruary 28, 2025 | markets.businessinsider.comThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being built at a classified government facility in Tennessee could make today's leading AI models obsolete overnight. He compares it to the iPhone moment that wiped out Nokia, BlackBerry, and Motorola. When this machine comes online, it will reportedly accelerate AI breakthroughs 360-fold - compressing five years of progress into five days. Navellier has identified specific stocks he'd sell before this hits, and one ticker he'd buy before May 5th. | InvestorPlace (Ad)Achilles Transfers Technology Assets From TRACERx NSCLC Study To AstraZeneca For $12 Mln, Stock UpDecember 24, 2024 | markets.businessinsider.comAchilles Therapeutics Announces Sale of Technology Assets to AstraZenecaDecember 24, 2024 | globenewswire.comAchilles Therapeutics PLC: Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketNovember 19, 2024 | finanznachrichten.deAchilles Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketNovember 19, 2024 | globenewswire.comAchilles Therapeutics PLC: Achilles Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | finanznachrichten.deSee More Headlines ACHL Stock Analysis - Frequently Asked Questions How were Achilles Therapeutics' earnings last quarter? Achilles Therapeutics plc (NASDAQ:ACHL) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.41) earnings per share for the quarter, hitting the consensus estimate of ($0.41). When did Achilles Therapeutics IPO? Achilles Therapeutics (ACHL) raised $176 million in an IPO on Tuesday, March 30th 2021. The company issued 9,750,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO. What other stocks do shareholders of Achilles Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Digital Turbine (APPS), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA). Company Calendar Last Earnings8/14/2024Today5/07/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACHL CIK1830749 Webwww.achillestx.com Phone44-0-20-8154-4600FaxN/AEmployees250Year Founded2016Profitability EPS (Trailing Twelve Months)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.67 million Net MarginsN/A Pretax MarginN/A Return on Equity-54.45% Return on Assets-47.68% Debt Debt-to-Equity RatioN/A Current Ratio6.04 Quick Ratio6.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.42Miscellaneous Outstanding Shares41,100,000Free Float38,889,000Market Cap$60.83 million OptionableNot Optionable Beta1.25 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ACHL) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy I flew on a tiny helicopter next to a potential nuclear bomb targetSatellite Confirms: Elon Musk Activating Strange 'Dark Energy' Across U.S. South Confirmed by satellites 30...Altimetry | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACHL Stock Alerts